glp-1 osteoarthritis Glucagon-like Peptide-1 Receptor Agonists in Management of Knee Osteoarthritis: A Meta-Analysis Two birds with one stone
Description
At-home blood test to assess GLP-1 therapy readiness
In patients with obesity (mean age 51.3 years, 65.6% women), semaglutide compared with non-GLP-1RA anti-obesity medications was associated with lower risk for incident CUD in patients with no prior history CUD (HR: 0.56, 95% CI: 0.420.75), and recurrent CUD diagnosis in patients with a prior history CUD (HR: 0.62, 95% CI: 0.460.84)
The researchers are planning a randomized trial to test whether benefits extend beyond weight to cardiovascular and metabolic markers
The unchanged US$9.88 fair value estimate for LifeMD keeps the core price target steady, even as model inputs see only marginal tweaks
Amplifies fullness signals so you eat less naturally
When you eat, []
